Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

  • ID: 4390722
  • Report
  • Region: Global
  • 113 Pages
  • GBI Research
1 of 4

Summary

Cardiovascular disease (CVD) is a broad therapy area containing a range of indications relating to the human vasculature, heart and lipid levels. There is considerable first-in-class innovation within the CVD pipeline, comparable with the industry average. The molecular target groups with the highest proportion of first-in-class products include lipid metabolism, transmembrane and extracellular signaling, intracellular signal transduction and ion channels.

Of the four key CVD indications identified in this report (hypertension, heart failure, dyslipidemia and thrombosis), the hypertensive pipeline is the largest, with 238 products in development. The pipelines for heart failure and dyslipidemia are also large. Drugs in development for thrombosis, and specifically the treatment or prevention of thrombosis itself (as opposed to managing the underlying risk factors) has a relatively small pipeline of just 104 products. Overall, there are 1,400 plus products in the CVD pipeline.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, The most promising first-in-class development within dyslipidemia focuses on targeting elements of the reverse lipid transport pathway. This is the process of high density lipoproteins (HDL) collecting cholesterol from cells, such as macrophages within atherosclerotic plaques, for removal from circulation in the liver via receptors such as scavenger receptor class B member 1 (SRB1).

Conventional classes of molecular target within the treatment of CVD are now showing relatively low levels of development, as innovation moves towards diverse targets related to the immune system, and transmembrane and extracellular signaling - with transmembrane proteins being a prominent source of innovation within the CVD pipeline.

This report has been designed to identify innovative pipeline programs across a therapy area with a focus on indications with high R&D activity and strong innovation, as well as a competitive commercial landscape and high levels of deal activity. Monitoring innovative new product developments is becoming an increasingly vital part of competitive intelligence for all market participants, and increasingly important for companies seeking strategic partnerships or looking to acquire technologies, products or other companies.

Scope

  • With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?
  • There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

Reasons to buy

  • Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
  • Visualize the composition of the CVD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the CVD pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating CVD to overcome the unmet need in the market.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals, and analyzing a curated list of CVD therapies that have not yet been involved in deals, and may offer potential investment opportunities.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents

2 Executive Summary
2.1 Robust pipeline with attempts to meet unmet need
2.2 Drugs targeting apolipoproteins and elements of the reverse lipid transport pathway offer potential new therapies for the treatment of dyslipidemia and atherosclerosis
2.3 Cardiovascular disease pipeline emphasizes move away from conventional areas towards targets related to transmembrane and extracellular signaling

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation in Cardiovascular Disease
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Cardiovascular Disease Overview
4.2 Symptoms, Disease Staging and Prognosis
4.2.1 Symptoms
4.2.2 Prognosis
4.3 Diagnosis
4.3.1 Blood Pressure Test
4.3.2 Tests for Dyslipidemia
4.3.3 Imaging Tests
4.3.4 Stress Testing
4.4 Epidemiology
4.5 Etiology and Pathophysiology
4.5.1 Etiology
4.5.2 Pathophysiology
4.6 Management and Treatment of Cardiovascular Disease
4.6.1 Pharmacological Intervention
4.6.2 Non-pharmacological Intervention
4.6.3 Unmet Need
4.7 Overview of Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.2.1 Cardiovascular Disease Overall
5.2.2 Key Cardiovascular Indications
5.3 Pipeline by Molecular Target
5.3.1 Cardiovascular Disease
5.3.2 Key Cardiovascular Indications
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.5 First-in-Class Programs Targeting Novel Molecular Targets
5.5.1 Cardiovascular Disease

6 Signaling Network and Innovation Alignment within Cardiovascular Disease
6.1 Complexity of Signaling Networks in Cardiovascular Disease
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Apelin Receptor
7.2 Pipeline Programs Targeting Apolipoproteins (Apolipoprotein E, Apolipoprotein C-III and Apolipoprotein A-I)
7.2.1 APOE
7.2.2 APOCIII
7.2.3 ApoA1
7.3 Pipeline Programs Targeting Scavenger Receptor Class B Member 1 (SRB1)
7.4 Pipeline Programs Targeting Cholesteryl Ester Transfer Protein (CETP)
7.5 Pipeline Programs Targeting Glutamyl Aminopeptidase
7.6 Pipeline Programs Targeting E-selectin
7.7 Pipeline Programs Targeting Platelet Glycoproteins (Platelet Glycoprotein VI and Platelet Glycoprotein Ib Alpha Chain)
7.7.1 Platelet Glycoprotein VI (GP6)
7.7.2 Platelet Glycoprotein Ib Alpha Chain (GP1ba)
7.8 Pipeline Programs Targeting Tissue Factor
7.9 Conclusion

8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.2.1 Deals by Region, Value and Year
8.2.2 Deals by Stage of Development and Value
8.2.3 Deals by Molecule Type, Molecular Target and Value
8.2.4 List of Deals with Disclosed Deal Values
8.3 Co-development Deals
8.3.1 Deals by Region, Value and Year
8.3.2 Deals by Region, Year and Value
8.3.3 Deals by Stage of Development and Value
8.3.4 Deals by Molecule Type, Molecular Target and Value
8.3.5 List of Deals with Disclosed Deal Values
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Disease List
9.3.1 Hypertension
9.3.2 Dyslipidemia
9.3.3 Heart failure
9.3.4 Thrombosis
9.3.5 CVD events
9.3.6 Other
9.4 Research Methodology
9.4.1 Data integrity
9.4.2 Innovative and meaningful analytical techniques and frameworks:
9.4.3 Evidence based analysis and insight:
9.5 Secondary Research
9.5.1 Market Analysis
9.5.2 Pipeline Analysis
9.5.3 First-in-Class Matrix Assessment
9.5.4 First-in-Class Target Profiles
9.5.5 Licensing and Co-Development Deals

List of Tables
Table 1: Cardiovascular Disease Therapeutics Market, Systolic and Diastolic Blood Pressure Level and Corresponding Category
Table 2: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category
Table 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, Forecast 2017
Table 4: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Apelin Receptor, 2017
Table 5: Cardiovascular Therapeutics Market, Global, Pipeline Programs Targeting Apelin Receptor ,2017
Table 6: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein E, 2017
Table 7: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein E, 2017
Table 8: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-CIII, 2017
Table 9: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein-CIII, 2017
Table 10: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-A1, 2017
Table 11: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoportein-A1, 2017
Table 12: Cardiovascular Disease Therapeutics Market, Global, Key Features of SRB1, 2017
Table 13: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting SRB1, 2017
Table 14: Cardiovascular Therapeutics Market, Global, Key Features of CETP, 2017
Table 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting CETP, 2017
Table 16: Cardiovascular Disease Therapeutics Market, Global, Key Features of Glutamyl Aminopeptidase, 2017
Table 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Glutamyl Aminopeptidase, 2017
Table 18: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of E-selectin, 2017
Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting E-selectin, 2017
Table 20: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein VI, 2017
Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein VI, 2017
Table 22: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein Ib Alpha Chain, 2017
Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein Ib Alpha Chain, 2017
Table 24: Cardiovascular Disease Therapeutics Market, Global, Key Features of Tissue Factor, 2017
Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Tissue Factor, 2017

List of Figures
Figure 1: Cardiovascular Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987-2014
Figure 2: Cardiovascular Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
Figure 3: Cardiovascular Disease and Associated Indications, Global, Cardiovascular Disease Market by Molecular Target, 2017
Figure 4: Cardiovascular Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017
Figure 5: Cardiovascular Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017
Figure 6: Hypertension, Dyslipidemia, Thrombotic events, and Heart Failure, Global, Pipelines by Stage of Development, 2017
Figure 7: Hypertension, Dyslipidemia, Thrombotic Events, and Heart Failure, Global, Pipelines by Molecule Type, 2017
Figure 8: Cardiovascular Disease, Global, Pipeline by Molecular Target, 2017
Figure 9: Cardiovascular Disease, Global, Pipeline by Molecular Target Breakdown, 2017
Figure 10: Hypertension, Dyslipidemia, Thrombotic Events, Heart Failure, Global, Pipelines by Molecular Target, 2017
Figure 11: Cardiovascular Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017
Figure 12: Cardiovascular Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017
Figure 13: Cardiovascular Disease Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target (%), 2017
Figure 14: Cardiovascular Disease Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target, 2017
Figure 15: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 1
Figure 16: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 2
Figure 17: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 3
Figure 18: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 4
Figure 19: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 5
Figure 20: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 6
Figure 21: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 7
Figure 22: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 8
Figure 23: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 9
Figure 24: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 10
Figure 25: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 11
Figure 26: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 12
Figure 27: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 13
Figure 28: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 14
Figure 29: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 15
Figure 30: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Hypertension, 2017
Figure 31: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Heart Failure, 2017
Figure 32: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Dyslipidemia, 2017
Figure 33: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Thrombosis, 2017
Figure 34: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Other Atherosclerotic Cardiovascular Disease Indications, 2017
Figure 35: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Deals by Stage of Development and First-in-Class Status, 2006-2017
Figure 36: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2017
Figure 37: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006-2017
Figure 38: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017
Figure 39: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017
Figure 40: Cardiovascular Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017
Figure 41: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006-2017
Figure 42: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 43: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017
Figure 44: Cardiovascular Disease Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017
Figure 45: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 1
Figure 46: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 2
Figure 47: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 3

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll